Entera's EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected

Core Insights - Entera Bio Ltd. is advancing its investigational agent EB613, an oral anabolic therapy for post-menopausal women with high-risk osteoporosis, with new pharmacological data to be presented at the ASBMR 2024 Annual Meeting [1][2][3] Company Overview - Entera Bio is focused on developing orally delivered peptides and therapeutic proteins, leveraging its proprietary N-Tab™ technology platform [4] - The company has a pipeline that includes five differentiated oral peptide programs expected to enter clinical trials by 2025 [4] Product Development - EB613 is designed as the first once-daily oral PTH(1-34) mini tablet therapy for post-menopausal women, addressing a significant unmet medical need in osteoporosis treatment [2][3] - Approximately 200 million women globally are affected by post-menopausal osteoporosis, which poses a serious health risk [2] - A Phase 2 study of EB613 met primary and secondary endpoints, and the company is preparing for a Phase 3 registrational study pending FDA qualification of bone mineral density as a surrogate endpoint [4] Upcoming Events - New comparative pharmacological data for EB613 will be presented at the ASBMR 2024 Annual Meeting, scheduled for September 27-30, 2024, in Toronto, Canada [1][4] - The SABRE project update will also be presented, highlighting the FDA's communication regarding bone mineral density as a regulatory endpoint [3][4]